Group 1 - Titan Technology's stock rose by 9.83% to 28.16 CNY per share, with a trading volume of 15.98 million CNY and a turnover rate of 0.35%, resulting in a total market capitalization of 4.631 billion CNY [1] - The company, established on October 18, 2007, and listed on October 30, 2020, provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart lab equipment, research informatization, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology includes 42.70% from research reagents, 28.42% from research instruments and consumables, 26.48% from specialty chemicals, 2.37% from laboratory construction and research informatization, and 0.02% from other sources [1] Group 2 - Nord Fund has a significant holding in Titan Technology, with the Nord Quantitative Core A fund (006267) owning 55,100 shares, representing 1.04% of the fund's net value, making it the seventh-largest holding [2] - The Nord Quantitative Core A fund was established on November 22, 2018, with a latest scale of 93.2332 million CNY, achieving a year-to-date return of 4.45% and a one-year return of 51.39% [2] - The fund manager, Wang Hengnan, has been in position for 7 years and 54 days, with total assets under management of 24.5 million CNY and a best fund return of 59.71% during his tenure [3]

Core Viewpoint - Titan Technology announced the renewal of the "Joint Action Agreement" among its actual controllers to ensure effective control and stable operations of the company as the original agreement is set to expire on December 27, 2024 [2] Group 1 - The renewal of the "Joint Action Agreement" was communicated by the actual controllers of Titan Technology, including Xie Yingbo, Zhang Qing, Zhang Hua, Xu Fengyuan, Wang Jingyu, and Zhang Weiyan [2] - The original "Joint Action Agreement" was signed on December 27, 2024, and is approaching its expiration date [2] - The renewal aims to enhance corporate governance and ensure continuity in the company's operations [2]

Core Viewpoint - Titan Technology (688133.SH) has announced the renewal of the "Consistent Action Agreement" among its actual controllers to ensure effective control and stable operations of the company as the original agreement is set to expire on December 27, 2024 [1] Group 1 - The actual controllers involved in the renewal include Xie Yingbo, Zhang Qing, Zhang Hua, Xu Fengyuan, Wang Jingyu, and Zhang Weiyan [1] - The renewal aims to enhance corporate governance and ensure continuity in the company's operations [1] - The original "Consistent Action Agreement" was signed on December 27, 2024, and is approaching its expiration [1]

Core Viewpoint - Titan Technology (688133.SH) has announced the renewal of the "Consistent Action Agreement" among its actual controllers to ensure effective control and stable operations of the company as the original agreement is set to expire on December 27, 2024 [1] Group 1 - The actual controllers involved in the renewal include Mr. Xie Yingbo, Mr. Zhang Qing, Mr. Zhang Hua, Mr. Xu Fengyuan, Mr. Wang Jingyu, and Ms. Zhang Weiyan [1] - The renewal aims to enhance corporate governance and ensure continuity in the company's operations [1] - The original "Consistent Action Agreement" was signed on December 27, 2024, and is approaching its expiration [1]

证券代码：688133 证券简称：泰坦科技 公告编号：2025-050 上海泰坦科技股份有限公司 关于公司实际控制人续签一致行动人协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日收到 公司实际控制人谢应波先生、张庆先生、张华先生、许峰源先生、王靖宇先生、 张维燕女士关于续签《一致行动人协议》的通知。鉴于各方在 2024 年 12 月 27 日 签署的《一致行动人协议》（以下简称"原《一致行动人协议》"）即将到期， 为完善公司治理，保证公司经营的连续性和稳定性，实现对公司实质且有效的控 制，各方续签了《一致行动人协议》，具体情况如下： 一、本次续签《一致行动人协议》的背景情况 截至本公告披露日，谢应波先生担任公司董事长，持有公司 9.88%的股份； 张庆先生担任公司董事、总经理，持有公司 4.59%的股份；张华先生担任公司董 事、副总经理，持有公司 4.59%的股份；许峰源先生担任公司董事，持有公司 4.58%的股份；王靖宇先生担任公 ...

Core Viewpoint - Titan Technology announced the renewal of the "Consistent Action Agreement" among its controlling shareholders, ensuring stability in the company's control and governance structure [1] Group 1 - The controlling shareholders, including Xie Yingbo, Zhang Qing, Zhang Hua, Xu Fengyuan, Wang Jingyu, and Zhang Weiyan, collectively hold 29.57% of the company's shares as of the announcement date [1] - The original agreement was signed on December 27, 2024, with a validity of one year, and the renewed agreement will also be valid for one year [1] - The agreement stipulates that the parties will act in concert on major company matters, with the opinions of the first party taking precedence in case of disagreement [1]

Core Viewpoint - Titan Technology announced the acquisition of 100% equity in Apollo Scientific Ltd. from Central Glass Co., Ltd., marking a significant step in its overseas expansion strategy [3][4]. Group 1: Acquisition Details - The acquisition was approved during the 17th meeting of the fourth board of directors on July 23, 2025 [3]. - Titan Technology has completed all necessary foreign investment filings and approvals, including obtaining certificates from the Shanghai Municipal Commission of Commerce and the Shanghai Development and Reform Commission [3]. - The transaction has passed the national security review in the UK, and all conditions for the deal's completion have been met [3][4]. Group 2: Strategic Implications - Following the completion of the acquisition, Apollo Scientific Ltd. will become a wholly-owned subsidiary of Titan Technology and will be included in the company's consolidated financial statements [4]. - The integration of Apollo Scientific is expected to enhance Titan Technology's product offerings and create synergies, including the establishment of overseas production and operational entities [4]. - This acquisition accelerates Titan Technology's global expansion efforts and aims to integrate the entire supply chain on a global scale [4].

Core Viewpoint - Titan Technology has successfully completed the acquisition of ASL, marking a significant step in its overseas expansion strategy and enhancing its operational capabilities in the chemical industry [1][3]. Group 1: Acquisition Details - The acquisition of 100% equity in ASL has been finalized, with all necessary foreign investment filings and approvals obtained, including certificates from the Shanghai Municipal Commission of Commerce and the Shanghai Development and Reform Commission [1]. - The total acquisition cost was £5.7564 million (approximately RMB 55.85 million), which has been fully paid to the seller, Central Glass Japan [1]. - ASL will be integrated into Titan Technology's consolidated financial statements as a wholly-owned subsidiary [1]. Group 2: ASL's Business Overview - ASL specializes in the distribution and customized services of chemical products, serving a diverse clientele that includes global pharmaceutical companies, biotechnology firms, academic research institutions, and chemical enterprises [2]. - The company offers over 100,000 types of compounds, including intermediates, fluorides, and life science reagents, ensuring a wide range of solutions for its customers [2]. - ASL has its own laboratories to maintain product quality and supply chain reliability, and it operates inventory locations in both the UK and the US [2]. Group 3: Strategic Implications - The acquisition aligns with Titan Technology's strategic development goals, promising enhancements in innovation, overseas production, and operational capabilities [3]. - Post-acquisition, the company plans to integrate ASL into its global supply chain, production technology, product development, and business teams, which is expected to strengthen profitability over time [2][3]. - ASL's business has faced cyclical downturns, with losses reported in 2023 and 2024, but a reduction in losses is anticipated for 2025 following the integration [2].

证券代码：688133 证券简称：泰坦科技 公告编号：2025-049 上海泰坦科技股份有限公司 关于收购境外公司股权的进展暨交割完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、交易情况概述 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"公司"）于 2025 年 7 月 23 日召开第四届董事会第十七次会议，审议通过了《关于拟收购境外公司股 权并签署股权收购协议的议案》。公司拟使用自有或自筹资金收购中央硝子株式 会社（即 Central Glass Co., Ltd，东京证券交易所上市公司，股票代码 4044， 以下简称"Central Glass 日本"）持有的 Apollo Scientific Ltd.（英格兰注 册的私人股份有限公司，以下简称"标的公司"或"ASL"）100%的股权。（以下 简称"本次交易"） 二、交易进展情况 公司已完成本次交易相关的境外投资备案及审批程序，并先后取得上海市商 委出具的《企业境外投资证书》、上海市发展和改革委员会出具的《境外投资项 目备案通知书》，并通过了英国投 ...

Core Viewpoint - Titan Technology announced the approval of a proposal to acquire 100% equity of Apollo Scientific Ltd. from Central Glass, with the transaction completed on July 23, 2025 [1] Group 1: Acquisition Details - The acquisition will be financed through the company's own or raised funds [1] - The company has completed the necessary overseas investment filing and approval procedures, passing the UK's national security review [1] - A delivery confirmation agreement has been signed, and the full acquisition payment has been made [1] Group 2: Post-Acquisition Status - Following the completion of the transaction, Apollo Scientific will become a wholly-owned subsidiary of Titan Technology [1] Group 3: Risks Associated - The transaction carries risks such as foreign exchange losses and uncertainties regarding integration effectiveness [1]